Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) – Stock analysts at Cantor Fitzgerald issued their FY2017 EPS estimates for shares of Aldeyra Therapeutics in a report released on Wednesday. Cantor Fitzgerald analyst E. Piros anticipates that the biotechnology company will earn ($1.30) per share for the year. Cantor Fitzgerald has a “Overweight” rating and a $22.00 price target on the stock. Cantor Fitzgerald also issued estimates for Aldeyra Therapeutics’ FY2018 earnings at ($1.29) EPS.

A number of other analysts also recently commented on the company. Zacks Investment Research downgraded Aldeyra Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, October 10th. ValuEngine downgraded Aldeyra Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, September 26th. Cowen and Company reaffirmed an “outperform” rating and set a $14.00 price target (up from $9.00) on shares of Aldeyra Therapeutics in a research report on Thursday, September 14th. Canaccord Genuity reaffirmed a “buy” rating and set a $27.00 price target (up from $12.00) on shares of Aldeyra Therapeutics in a research report on Wednesday, September 13th. Finally, HC Wainwright set a $18.00 price target on Aldeyra Therapeutics and gave the company a “buy” rating in a research report on Wednesday, August 9th. Two equities research analysts have rated the stock with a sell rating and five have given a buy rating to the company. Aldeyra Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $16.96.

ILLEGAL ACTIVITY NOTICE: This story was originally published by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another website, it was copied illegally and reposted in violation of United States & international trademark and copyright legislation. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/10/27/cantor-fitzgerald-weighs-in-on-aldeyra-therapeutics-inc-s-fy2017-earnings-aldx.html.

Aldeyra Therapeutics (NASDAQ:ALDX) opened at 6.25 on Friday. The firm’s market capitalization is $39.03 million. The company’s 50 day moving average price is $7.01 and its 200-day moving average price is $5.19. Aldeyra Therapeutics has a 12-month low of $3.80 and a 12-month high of $11.90.

Aldeyra Therapeutics (NASDAQ:ALDX) last posted its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.35) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.02.

In other news, major shareholder Life Sciences Maste Perceptive bought 200,000 shares of the firm’s stock in a transaction on Tuesday, September 19th. The stock was acquired at an average cost of $7.25 per share, with a total value of $1,450,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 28.40% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in ALDX. Virtu KCG Holdings LLC purchased a new position in shares of Aldeyra Therapeutics in the second quarter valued at $104,000. Renaissance Technologies LLC purchased a new position in shares of Aldeyra Therapeutics in the first quarter valued at $132,000. Hikari Power Ltd grew its position in shares of Aldeyra Therapeutics by 186.4% in the second quarter. Hikari Power Ltd now owns 107,858 shares of the biotechnology company’s stock valued at $507,000 after purchasing an additional 70,196 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Aldeyra Therapeutics by 3.2% in the second quarter. Vanguard Group Inc. now owns 304,633 shares of the biotechnology company’s stock valued at $1,431,000 after purchasing an additional 9,407 shares in the last quarter. Finally, Sphera Funds Management LTD. grew its position in shares of Aldeyra Therapeutics by 31.0% in the second quarter. Sphera Funds Management LTD. now owns 875,931 shares of the biotechnology company’s stock valued at $4,117,000 after purchasing an additional 207,431 shares in the last quarter. 40.32% of the stock is owned by institutional investors and hedge funds.

About Aldeyra Therapeutics

Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.

Receive News & Ratings for Aldeyra Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.